Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers

Lakshmi Prabhu, Han Wei, Lan Chen, Özlem Demir, George Sandusky, Emily Sun, John Wang, Jessica Mo, Lifan Zeng, Melissa Fishel, Ahmad Safa, Rommie Amaro, Murray Korc, Zhong-Yin Zhang, Tao Lu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are notoriously challenging for treatment. Hyperactive nuclear factor κB (NF-κB) is a common culprit in both cancers. Previously, we discovered that protein arginine methyltransferase 5 (PRMT5) methylated and activated NF-κB. Here, we show that PRMT5 is highly expressed in PDAC and CRC. Overexpression of PRMT5 promoted cancer progression, while shRNA knockdown showed an opposite effect. Using an innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-LL-CM01, which exhibited robust tumor inhibition effects in both cancers. An in silico structure prediction suggested that PR5-LL-CM01 inhibits PRMT5 by binding with its active pocket. Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC. This study clearly highlights the significant potential of PRMT5 as a therapeutic target in PDAC and CRC, and establishes PR5-LL-CM01 as a promising basis for new drug development in the future.

Original languageEnglish (US)
Pages (from-to)39963-39977
Number of pages15
JournalOncotarget
Volume8
Issue number25
DOIs
StatePublished - 2017

Fingerprint

Protein-Arginine N-Methyltransferases
Pancreatic Neoplasms
Colorectal Neoplasms
Adenocarcinoma
Neoplasms
Computer Simulation
Small Interfering RNA
Pharmaceutical Preparations

Keywords

  • AlphaLISA
  • Colorectal cancer
  • Pancreatic ductal adenocarcinoma
  • PRMT5
  • Small-molecule inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. / Prabhu, Lakshmi; Wei, Han; Chen, Lan; Demir, Özlem; Sandusky, George; Sun, Emily; Wang, John; Mo, Jessica; Zeng, Lifan; Fishel, Melissa; Safa, Ahmad; Amaro, Rommie; Korc, Murray; Zhang, Zhong-Yin; Lu, Tao.

In: Oncotarget, Vol. 8, No. 25, 2017, p. 39963-39977.

Research output: Contribution to journalArticle

Prabhu, Lakshmi ; Wei, Han ; Chen, Lan ; Demir, Özlem ; Sandusky, George ; Sun, Emily ; Wang, John ; Mo, Jessica ; Zeng, Lifan ; Fishel, Melissa ; Safa, Ahmad ; Amaro, Rommie ; Korc, Murray ; Zhang, Zhong-Yin ; Lu, Tao. / Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. In: Oncotarget. 2017 ; Vol. 8, No. 25. pp. 39963-39977.
@article{95d3c0f109bb42a49c3ee1ced8b4f20b,
title = "Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are notoriously challenging for treatment. Hyperactive nuclear factor κB (NF-κB) is a common culprit in both cancers. Previously, we discovered that protein arginine methyltransferase 5 (PRMT5) methylated and activated NF-κB. Here, we show that PRMT5 is highly expressed in PDAC and CRC. Overexpression of PRMT5 promoted cancer progression, while shRNA knockdown showed an opposite effect. Using an innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-LL-CM01, which exhibited robust tumor inhibition effects in both cancers. An in silico structure prediction suggested that PR5-LL-CM01 inhibits PRMT5 by binding with its active pocket. Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC. This study clearly highlights the significant potential of PRMT5 as a therapeutic target in PDAC and CRC, and establishes PR5-LL-CM01 as a promising basis for new drug development in the future.",
keywords = "AlphaLISA, Colorectal cancer, Pancreatic ductal adenocarcinoma, PRMT5, Small-molecule inhibitor",
author = "Lakshmi Prabhu and Han Wei and Lan Chen and {\"O}zlem Demir and George Sandusky and Emily Sun and John Wang and Jessica Mo and Lifan Zeng and Melissa Fishel and Ahmad Safa and Rommie Amaro and Murray Korc and Zhong-Yin Zhang and Tao Lu",
year = "2017",
doi = "10.18632/oncotarget.18102",
language = "English (US)",
volume = "8",
pages = "39963--39977",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers

AU - Prabhu, Lakshmi

AU - Wei, Han

AU - Chen, Lan

AU - Demir, Özlem

AU - Sandusky, George

AU - Sun, Emily

AU - Wang, John

AU - Mo, Jessica

AU - Zeng, Lifan

AU - Fishel, Melissa

AU - Safa, Ahmad

AU - Amaro, Rommie

AU - Korc, Murray

AU - Zhang, Zhong-Yin

AU - Lu, Tao

PY - 2017

Y1 - 2017

N2 - Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are notoriously challenging for treatment. Hyperactive nuclear factor κB (NF-κB) is a common culprit in both cancers. Previously, we discovered that protein arginine methyltransferase 5 (PRMT5) methylated and activated NF-κB. Here, we show that PRMT5 is highly expressed in PDAC and CRC. Overexpression of PRMT5 promoted cancer progression, while shRNA knockdown showed an opposite effect. Using an innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-LL-CM01, which exhibited robust tumor inhibition effects in both cancers. An in silico structure prediction suggested that PR5-LL-CM01 inhibits PRMT5 by binding with its active pocket. Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC. This study clearly highlights the significant potential of PRMT5 as a therapeutic target in PDAC and CRC, and establishes PR5-LL-CM01 as a promising basis for new drug development in the future.

AB - Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are notoriously challenging for treatment. Hyperactive nuclear factor κB (NF-κB) is a common culprit in both cancers. Previously, we discovered that protein arginine methyltransferase 5 (PRMT5) methylated and activated NF-κB. Here, we show that PRMT5 is highly expressed in PDAC and CRC. Overexpression of PRMT5 promoted cancer progression, while shRNA knockdown showed an opposite effect. Using an innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-LL-CM01, which exhibited robust tumor inhibition effects in both cancers. An in silico structure prediction suggested that PR5-LL-CM01 inhibits PRMT5 by binding with its active pocket. Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC. This study clearly highlights the significant potential of PRMT5 as a therapeutic target in PDAC and CRC, and establishes PR5-LL-CM01 as a promising basis for new drug development in the future.

KW - AlphaLISA

KW - Colorectal cancer

KW - Pancreatic ductal adenocarcinoma

KW - PRMT5

KW - Small-molecule inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85021042124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021042124&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18102

DO - 10.18632/oncotarget.18102

M3 - Article

AN - SCOPUS:85021042124

VL - 8

SP - 39963

EP - 39977

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -